IL188728A0 - Methods of treating epileptogenesis - Google Patents

Methods of treating epileptogenesis

Info

Publication number
IL188728A0
IL188728A0 IL188728A IL18872808A IL188728A0 IL 188728 A0 IL188728 A0 IL 188728A0 IL 188728 A IL188728 A IL 188728A IL 18872808 A IL18872808 A IL 18872808A IL 188728 A0 IL188728 A0 IL 188728A0
Authority
IL
Israel
Prior art keywords
methods
treating epileptogenesis
epileptogenesis
treating
Prior art date
Application number
IL188728A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL188728(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL188728A0 publication Critical patent/IL188728A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL188728A 2005-07-12 2008-01-10 Methods of treating epileptogenesis IL188728A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69862505P 2005-07-12 2005-07-12
PCT/US2006/026277 WO2007008551A2 (en) 2005-07-12 2006-07-07 Use of 2-phenyl-l, 2-ethanedi0l-(di) carbamates for treating epileptogenesis and epilepsy

Publications (1)

Publication Number Publication Date
IL188728A0 true IL188728A0 (en) 2008-11-03

Family

ID=37637731

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188728A IL188728A0 (en) 2005-07-12 2008-01-10 Methods of treating epileptogenesis

Country Status (16)

Country Link
US (1) US20070021501A1 (enExample)
EP (1) EP1906946A2 (enExample)
JP (1) JP2009501223A (enExample)
KR (1) KR20080028485A (enExample)
CN (1) CN101309680A (enExample)
AR (1) AR054550A1 (enExample)
AU (1) AU2006269462A1 (enExample)
BR (1) BRPI0613010A2 (enExample)
CA (1) CA2615127A1 (enExample)
EA (1) EA200800295A1 (enExample)
EC (1) ECSP088172A (enExample)
IL (1) IL188728A0 (enExample)
NO (1) NO20080739L (enExample)
TW (1) TW200744575A (enExample)
WO (1) WO2007008551A2 (enExample)
ZA (1) ZA200801402B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JP6062077B2 (ja) 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR102615486B1 (ko) * 2015-08-24 2023-12-19 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
CN109071424B (zh) * 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
US20190022166A1 (en) * 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
JP2002536409A (ja) * 1999-02-09 2002-10-29 ユニバーシティ オブ バージニア パテント ファウンデーション フェルバメートから誘導される化合物
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder

Also Published As

Publication number Publication date
JP2009501223A (ja) 2009-01-15
TW200744575A (en) 2007-12-16
BRPI0613010A2 (pt) 2010-12-14
KR20080028485A (ko) 2008-03-31
CA2615127A1 (en) 2007-01-18
CN101309680A (zh) 2008-11-19
WO2007008551A3 (en) 2008-06-19
US20070021501A1 (en) 2007-01-25
EP1906946A2 (en) 2008-04-09
AR054550A1 (es) 2007-06-27
EA200800295A1 (ru) 2008-12-30
ECSP088172A (es) 2008-03-26
WO2007008551A2 (en) 2007-01-18
AU2006269462A1 (en) 2007-01-18
NO20080739L (no) 2008-04-10
ZA200801402B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
IL183889A0 (en) Treatment method
IL190913A0 (en) Methods for the treatment of hyperhidrosis
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
IL182011A0 (en) Treatment screening methods
IL186408A0 (en) Combination treatment methods
EP2032131A4 (en) Methods of Treatment
IL188331A0 (en) Method for the treatment of acne
GB0521944D0 (en) Method of treating gas
IL185757A0 (en) Methods of decreasing calcifcation
ZA200704610B (en) Treatment apparatus
IL184330A0 (en) Treatment apparatus
GB0610746D0 (en) Method of treatment
GB0502656D0 (en) Treatment of metakaolin
GB0516068D0 (en) Well treatment
ZA200709024B (en) Method of well treatment and construction
GB0426196D0 (en) Methods of treatment
GB0525540D0 (en) New treatment
GB0511769D0 (en) Treatment
IL226362A0 (en) compounds, and methods for treating cancer
EP1809276A4 (en) PROCESSING PROCESS
EP1793813A4 (en) TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
GB0502171D0 (en) Well treatment
GB2424579B (en) Method of treating hair
GB0522330D0 (en) Method of treatment
EP1871404A4 (en) ANTI-ASTHMATIC TREATMENT